BrightSpring Health Services, Inc. - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. BrightSpring Health Services, Inc. is a leading home and community-based healthcare platform operating two primary segments: Pharmacy Solutions and Provider Services. The Company serves over 460,000 patients daily across all 50 states. A significant strategic development is the pending divestiture of its Community Living business (including home and community-based waiver programs and intermediate care facilities) to National Mentor Holdings, Inc. for $835 million. This divestiture is classified as discontinued operations and is expected to close in Q1 2026.
Key Financial Metrics (Nine Months Ended Sept 30, 2025)
| Metric | 9 Months 2025 | 9 Months 2024 | Change |
|---|---|---|---|
| Total Revenue | $9,359.9 million | $7,325.2 million | +27.8% |
| Net Income (Continuing Ops) | $55.2 million | $(73.2) million | Turnaround to Profit |
| Net Income (Total) | $111.8 million | $(35.9) million | +128.5 million |
| Operating Income | $187.1 million | $52.4 million | +257.0% |
| Adjusted EBITDA | $434.0 million | $329.8 million | +31.6% |
| Diluted EPS | $0.52 | $(0.18) | Improvement |
| Cash from Operations | $258.6 million | $(66.8) million | +325.4 million |
| Total Debt (Gross) | $2,582.1 million | $2,683.3 million | -3.8% |
| Total Liquidity | $617.6 million | $475.8 million | +29.8% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Pharmacy Solutions segment, which grew 31.0% in Q3 and 30.4% YTD, fueled by volume growth in Infusion and Specialty Pharmacy. Provider Services grew 9.4% in Q3 and 10.6% YTD.
- Profitability: The Company returned to profitability in continuing operations, reporting net income of $55.2 million for the nine months ended Sept 30, 2025, compared to a net loss of $73.2 million in the prior year. This was driven by increased gross profit and reduced interest expense.
- Interest Expense: Net interest expense decreased by 17.7% YTD to $118.8 million, attributed to lower variable interest rates and reduced outstanding term debt.
- Discontinued Operations: The Community Living business contributed $56.5 million in net income for the nine months ended Sept 30, 2025, and is now reported separately as discontinued operations.
- Legal Settlements: The $120 million Silver matter settlement was fully paid by April 2025 ($110 million in 2024, $10 million in 2025), removing a significant cash outflow burden in the current period.
Guidance, Outlook, and Risks
Outlook: Management expects the divestiture of the Community Living business to streamline service offerings, increase strategic focus on senior and specialty populations, and augment revenue and Adjusted EBITDA growth rates. The Company anticipates continued growth in pharmacy patient census and provider services due to demographic trends and the shift toward home-based care.
Risks and Contingencies:
- Regulatory & Reimbursement: Dependence on Medicare and Medicaid reimbursement rates, which are subject to legislative changes and cost containment initiatives.
- Divestiture Execution: The $835 million sale of the Community Living business is subject to regulatory approvals and customary closing conditions.
- Debt Obligations: The Company carries substantial indebtedness (~$2.6 billion) and is subject to financial covenants, including a leverage ratio test.
- Operational Risks: Challenges in recruiting and retaining qualified personnel (nurses, pharmacists) and potential supply chain disruptions affecting drug costs.
Investor Verification Checklist
- Divestiture Timeline: Verify the closing status of the $835 million Community Living business sale to National Mentor Holdings, expected in Q1 2026.
- Debt Covenants: Confirm continued compliance with the First Lien Credit Agreement leverage ratio (reported at 3.31x as of Sept 30, 2025).
- Pharmacy Mix: Analyze the sustainability of the 31.9% increase in revenue per script, driven by specialty drug mix shifts.
- TEU Settlement: Monitor the conversion of 8 million Tangible Equity Units (TEUs) due February 2027, which could impact share count and dilution.
- Legal Reserves: Review Note 13 for updates on the Silver matter settlement and any new legal contingencies.